Allogene Therapeutics (ALLO) Shares Outstanding (Weighted Average) (2017 - 2026)

Allogene Therapeutics has disclosed Shares Outstanding (Weighted Average) across 10 years of filings, most recently posting $240.3 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $240.3 million, up 11.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $240.3 million (up 11.58% YoY), and the FY2025 annual result was $220.6 million, up 13.25% from the prior year.
• Shares Outstanding (Weighted Average) came in at $240.3 million for Q1 2026 at Allogene Therapeutics, up from $220.6 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $240.3 million in Q1 2026 to a low of $141.4 million in Q1 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $169.1 million (2024), against an average of $180.5 million.
• Across the five-year window, Shares Outstanding (Weighted Average) increased 2.27% in 2023 and rose 29.45% in 2024, its largest moves.
• Allogene Therapeutics' Shares Outstanding (Weighted Average) stood at $143.1 million in 2022, then increased by 9.63% to $156.9 million in 2023, then increased by 24.14% to $194.8 million in 2024, then advanced by 13.25% to $220.6 million in 2025, then climbed by 8.91% to $240.3 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $240.3 million (Q1 2026), $220.6 million (Q4 2025), and $222.0 million (Q3 2025), per Business Quant data.